TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06164275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV
Study: NCT05995860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group triads
Description: The intervention consists of a rapid (less than 10-minute) communication intention elicitation exercise (via Freelisting), which is conducted independently with the patient, caregiver, and provider immediately prior to the outpatient oncology encounter. Patients, caregivers, and providers will not be instructed to endorse the Freelist responses that were generated by the intervention prior to the outpatient encounter-leaving the decision to discuss elicited communication intentions during the encounter up to individuals as the conversation naturally occurs. As with the control group, post-encounter survey data will also be collected independently from the patient, caregiver, and the provider, followed by a post-encounter qualitative interview conducted jointly with the patient and caregiver.
Study: NCT06172478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: Intravenous infusion 5.6 mg/kg administered Q3W on Day 1 of each 21-day cycle
Study: NCT05216276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEP
Description: Laparoscopic totally extra-peritoneal (TEP) inguinal hernia repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rTAPP
Description: robotic transabdominal preperitoneal (TAPP) inguinal hernia repair
Study: NCT04705896

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20-25% Albumin fluid (100 mL)
Description: Participants will be randomized to receive albumin (20-25%) during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (i.e. for SLED sessions, at 0 and 4 hours; for IHD sessions, at 0 and 2 hours).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline (100 mL)
Description: Participants will be randomized to receive normal saline 100 mL boluses during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (e.g. for 8 hour SLED sessions, at 0 and 4 hours; for 4 hour IHD sessions, at 0 and 2 hours; for CRRT, after starting/randomization then every 12 hours while continuing on CRRT).
Study: NCT04273022

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: A single bout of standardized, moderate exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A single bout of standardized, moderate exercise
Study: NCT06341933

Intervention type: OTHER
Intervention: Duration of Surgery
Description: Total surgery time in minutes

Intervention type: OTHER
Intervention: Duration of Surgery
Description: Total surgery time in minutes

Intervention type: OTHER
Intervention: Volume of Fluid in Surgery
Description: Fluid volume given during surgery in ml

Intervention type: OTHER
Intervention: Volume of Fluid in Surgery
Description: Fluid volume given during surgery in ml

Intervention type: OTHER
Intervention: Blood Loss
Description: Blood loss during surgery in ml

Intervention type: OTHER
Intervention: Blood Loss
Description: Blood loss during surgery in ml
Study: NCT05539209

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OKquit
Description: Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys plus OKquit Smartphone App including tailored messages and on-demand content designed to assist participants in their cessation attempt.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Helpline Care
Description: Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys.
Study: NCT05393479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking Healthy Programme
Description: The Thinking Healthy Programme (THP) is a psychological treatment recommended by the World Health Organization for perinatal depression. The THP is based on the basic tenets of cognitive behavioural therapy (CBT) that aims to identify unhealthy thoughts and the vicious effects it has on the emotions and behaviour of a person and transform to healthy thinking style that ultimately impacts one's emotions and behaviour, too. The intervention aims to bring positive outcomes in three areas - a) mother's health, b) the mother-baby relationship, and c) the mother's relationship with others. A randomized controlled trial (RCT) showed that the intervention was effective in reducing depressive symptoms and disability and improving functioning. Additionally, women receiving THP had higher rate of exclusive breastfeeding, and engaging more with their infants. Similarly, infants of these women were also less likely to have diarrhoeal episode and more likely to complete immunization.
Study: NCT05042973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matches the active drug in appearance, odor and labelling.
Study: NCT06519097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E Delta Tocotrienol
Description: Tocotrienols are natural vitamin E compounds that are known to have a neuroprotective effect at nanomolar concentration and anti-carcinogenic effect at micromolar concentration.~400 mg orally, twice daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo contains no active ingredients.~465 mg pure olive oil orally, twice daily
Study: NCT05385588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive functional assessment
Description: * Self-administered questionnaire~* Cognitive and functional tests~* Medical questionnaire~* Sampling for biobank (28-32 ml will be collected)
Study: NCT03862430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanO2TM
Description: 0.1 mL/kg NanO2 infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline Infusion
Description: Saline Infusion
Study: NCT04172532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy
Description: Undergo tissue collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study: NCT05775549

Intervention type: OTHER
Intervention: None (Observational Study)
Description: Not Applicable since observational study
Study: NCT04172532

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT06092333

Intervention type: DRUG
Group type: OTHER
Intervention: VIR-2218 and peginterferon alfa-2a
Description: (VIR-2218) administered as a lead-in followed by combination with peginterferon alfa-2a
Study: NCT05773274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05697068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Prevention Program (CPP)
Description: This project is a promotor/a-led COVID-19 Prevention Program (CPP) for Latino patients of a Federally Qualified Health Center (FQHC) who are recently diagnosed with SARS-CoV-2. The program will implement immediate risk reduction strategies to prevent household spread of COVID-19, followed by risk reduction strategies to prevent community spread. Patients and household members who agree to participate will be patients of the FQHC (the covered entity) and will have completed a broad consent that authorizes program activities (e.g., COVID-19 testing, individualized counseling). Patients are free to refuse to participate in the CPP without impact on other services they may receive at the clinic. Research activities will be managed by study's measurement team, which involves surveys conducted on index patients at baseline, 1-, 6-, 12-, and 24-months. Written informed consent will be obtained for all research activities occurring outside of clinical care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID Prevention Program (CPP)
Description: This project is a promotor/a-led COVID-19 Prevention Program (CPP) for Latino patients of a Federally Qualified Health Center (FQHC) who are recently diagnosed with SARS-CoV-2. The program will implement immediate risk reduction strategies to prevent household spread of COVID-19, followed by risk reduction strategies to prevent community spread. Patients and household members who agree to participate will be patients of the FQHC (the covered entity) and will have completed a broad consent that authorizes program activities (e.g., COVID-19 testing, individualized counseling). Patients are free to refuse to participate in the CPP without impact on other services they may receive at the clinic. Research activities will be managed by study's measurement team, which involves surveys conducted on index patients at baseline, 1-, 6-, 12-, and 24-months. Written informed consent will be obtained for all research activities occurring outside of clinical care.
Study: NCT06548581

Intervention type: DEVICE
Intervention: SpeedPlate™ Rapid Compression Implants
Description: MTP and/or TMT joint fixation with SpeedPlate™ Rapid Compression Implants
Study: NCT05941013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound detectable cuffed endotracheal tube (USD-ETT)
Description: Intubation with a novel ultrasound-detectable endotracheal tube
Study: NCT04671407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline
Description: Hypertonic Saline 3% and 0.9%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypertonic Saline
Description: Hypertonic Saline 3% and 0.9%
Study: NCT03895658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Structural and functional neuroimaging pre and post ECT treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro TMS stimulator and coil
Description: Transcranial magnetic stimulation measurements of cortical excitability pre and post ECT treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thymatron (R) System IV paired with 4X1 HDECT
Description: Multi-Channel Stimulation Interface (Model 4X1 HDECT)
Study: NCT06525064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-E You app
Description: When clinics are in the intervention condition, all patients presenting for any reason will get a study weblink 24 hours before the visit; walk-ins will get a study link code in clinic. If the participants agree to participate and meet study criteria, the participants will get a survey link and then Health-E You content to complete before the visit. Previously enrolled males will not be enrolled again to maintain the research study's integrity. Thus, participants will only have one opportunity for administration to the Health-E You app.~Participants will be considered to have completed the Health-E You app if the participants answer all of the app's initial tailoring questions and receive recommendations for SRH topics to discuss with the clinician. As a technology-based intervention, no direct interactions with interventionists with participants are required.
Study: NCT05630781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belsomra
Description: randomized, double-blind, placebo-controlled crossover design study: Participants will undergo a baseline scan followed by 2 acute drug administration scans where suvorexant or placebo is administered in a randomized manner where both the participant and study staff administering drug are blind. Following the second acute scan, participants will continue with the drug they received at Scan 2 for approximately 7 days. After the first chronic scan, participants will switch to the other drug for an additional \~7 days and then scanned a final time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belsomra
Description: randomized, double-blind, placebo-controlled crossover design study: Participants will undergo a baseline scan followed by 2 acute drug administration scans where suvorexant or placebo is administered in a randomized manner where both the participant and study staff administering drug are blind. Following the second acute scan, participants will continue with the drug they received at Scan 2 for approximately 7 days. After the first chronic scan, participants will switch to the other drug for an additional \~7 days and then scanned a final time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: comparator taken for \~10 days
Study: NCT05150847

Intervention type: OTHER
Group type: OTHER
Intervention: Oxygenation
Description: Oxygenation will be calculated as PaO2/ FiO2 ratio.Static compliance will be calculated as tidal volume divided driving pressure.The potential for lung recruitment will be assessed by means of the R/I ratio (10).
Study: NCT05630781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: comparator taken for \~10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Control Arm: Baseline visit with 2 fMRI scans pre- and post-20mg methylphenidate, 4 acute drug administration (6-14 days in randomized order: 1. Placebo + placebo; 2. 20mg suvorexant + Placebo; 3. Placebo + 40mg methylphenidate; 4. 20 mg suvorexant + 40mg methylphenidate max)
Study: NCT05887531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Patients will be included in a prehabilitation program
Study: NCT04956640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous
Study: NCT05435937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partnering for change (P4C-Swe)
Description: P4C focuses on the collaboration and a intersectional partnership between teachers and occupational therapists/special educators to create physical, social and learning environments that facilitate successful participation for all pupils. The intervention tiered model provides interventions in a school context in levels; class, group, and individual level to students with participation restrictions.~Dynamic Performance Analysis (DPA), which focuses on pupils' occupational performance, is used in P4C model to identify and analyze were and why pupils' occupational performance is breaking down in school-based occupations in the natural context, followed by collaboration and coaching between the occupational therapist and teacher in setting up goals, planning, implementing and monitoring intervention at the different intervention levels, to support participation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual is provided by the Student health services that consists of a school doctor, school nurse, psychologist and counselor, and staff with special educational competence
Study: NCT05811520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular stabilization exercises with conventional therapy
Description: The patient will sit on the knees in 90° flexion position, and a Swiss ball will be placed between the chest and stomach. From the side, the earlobe, acromion of scapula, and pelvis should made a straight line. Four general exercises will be included with 2 sets of 15 repetitions, holding for 10 sec

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic extension exercises with conventional therapy
Description: Thoracic extension exercises consist of three exercise protocols
Study: NCT05203757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ArthroCT scan
Description: Conventional CT arthrogram as routine care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBCT
Description: Cone Beam CT scan.
Study: NCT04956640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous
Study: NCT06006117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab + Lenalidomide
Description: * Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)~  * C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15~ * C2 to C12: 45 mg D1 28-days cycles~* Lenalidomide PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: - Rituximab + Lenalidomide (28-days cycles
Description: * Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: - Rituximab + Bendamustine (28-days cycles)
Description: * Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion~* Rituximab\* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6\*\* (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). \*\*For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: - Rituximab + CHOP (21-days cycles)
Description: * CHOP, IV standard dose from cycle 1 to 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)
Study: NCT05113433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session.